226 related articles for article (PubMed ID: 31714961)
21. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
[TBL] [Abstract][Full Text] [Related]
22. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
Leung W; Pui CH; Coustan-Smith E; Yang J; Pei D; Gan K; Srinivasan A; Hartford C; Triplett BM; Dallas M; Pillai A; Shook D; Rubnitz JE; Sandlund JT; Jeha S; Inaba H; Ribeiro RC; Handgretinger R; Laver JH; Campana D
Blood; 2012 Jul; 120(2):468-72. PubMed ID: 22517895
[TBL] [Abstract][Full Text] [Related]
23. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
Ram R; Storb R; Sandmaier BM; Maloney DG; Woolfrey A; Flowers ME; Maris MB; Laport GG; Chauncey TR; Lange T; Langston AA; Storer B; Georges GE
Haematologica; 2011 Aug; 96(8):1113-20. PubMed ID: 21508120
[TBL] [Abstract][Full Text] [Related]
24. Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia.
Umeda K; Hiramatsu H; Kawaguchi K; Iwai A; Mikami M; Nodomi S; Saida S; Heike T; Ohomori K; Adachi S
Pediatr Transplant; 2016 Aug; 20(5):692-6. PubMed ID: 27256540
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
[TBL] [Abstract][Full Text] [Related]
26. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.
Tomblyn MB; Arora M; Baker KS; Blazar BR; Brunstein CG; Burns LJ; DeFor TE; Dusenbery KE; Kaufman DS; Kersey JH; MacMillan ML; McGlave PB; Miller JS; Orchard PJ; Slungaard A; Tomblyn MR; Vercellotti GM; Verneris MR; Wagner JE; Weisdorf DJ
J Clin Oncol; 2009 Aug; 27(22):3634-41. PubMed ID: 19581540
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
28. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
30. [Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].
Shi XL; Tang XW; Wei XA; Zhao BR; Zhou QL; Ye F; Lu YX; Sun XW; Zhu MQ; Shen WH; Qiu HY; Sun AN; Wu DP
Zhonghua Yi Xue Za Zhi; 2011 Oct; 91(38):2692-6. PubMed ID: 22321979
[TBL] [Abstract][Full Text] [Related]
31. Comparable outcomes of partially matched related and matched related allogeneic hematopoietic cell transplantation following reduced-intensity conditioning in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Wu X; He G; Fa Y; Ma X; Wu D; Ai H; Huang X; Han Y; Xu Y; Sun A; Wu Q; Tang X; Fu Z
Int J Hematol; 2013 Oct; 98(4):456-62. PubMed ID: 23975518
[TBL] [Abstract][Full Text] [Related]
32. Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.
Shah NN; Borowitz MJ; Steinberg SM; Robey NC; Gamper CJ; Symons HJ; Loeb DM; Wayne AS; Chen AR
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1033-9. PubMed ID: 24691222
[TBL] [Abstract][Full Text] [Related]
33. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
34. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival.
Bachanova V; Burke MJ; Yohe S; Cao Q; Sandhu K; Singleton TP; Brunstein CG; Wagner JE; Verneris MR; Weisdorf DJ
Biol Blood Marrow Transplant; 2012 Jun; 18(6):963-8. PubMed ID: 22430088
[TBL] [Abstract][Full Text] [Related]
35. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
[TBL] [Abstract][Full Text] [Related]
36. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
37. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
[TBL] [Abstract][Full Text] [Related]
39. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]